1073TiPA PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF IMPRIME PGG IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH KRAS WILD TYPE METASTATIC COLORECTAL CANCER von Patchen, M.L., Gargano, M., Grady, M., Lowe, J., Huhn, R.D., Braun, A.

Volltext

LBA32IMPRIME PGG, A NOVEL IMMUNE MODULATOR, IN THE 1ST-LINE TREATMENT OF STAGE IV NSCLC: RESULTS FROM A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 2 STUDY von Engel-Riedel, W., Schneller, F., Wolf, M., Schuette, W., Lowe, J., Mattson, P., Gargano, M., Patchen, M.L., Huhn, R.D., Braun, A.

Volltext

Imprime Pgg, a Novel Immune Modulator, in the 1St-Line Treatment of Stage Iv Nsclc: Results from a Randomized, Controlled, Multicenter Phase 2 Study von Engel-Riedel, W., Schneller, F., Wolf, M., Schuette, W., Lowe, J., Mattson, P., Gargano, M., Patchen, M.L., Huhn, R.D., Braun, A.

Volltext

Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning von HUHN, R. D, TISDALE, J. F, AGRICOLA, B, METZGER, M. E, DONAHUE, R. E, DUNBAR, C. E

Volltext

P-298 Stimulation of granulocyte colony stimulating factor (G-CSF) and leukocytosis in women receiving menotropin therapy von Hock, D.L, Huhn, R.D, Kemmann, E

Volltext